Group structure
13 companies in 8 countries
Loading your page…
Loading your page…
13 companies in 8 countries
One free account for the Prognia apps: Ward to study, Osler for clinical answers with their sources, and the network to find your colleagues.
Groups are put together by Prognia from the names regulators publish and from company links; they are not an official corporate structure.
Every medicine of every company in the group, current ones first.
1–25 of 53
| Medicine | Substance | Country | Status | Authorised |
|---|---|---|---|---|
| ARTICAINE HYDROCHLORIDE AND EPINEPHRINE INJECTION - N40 mg / ml + 0.005 mg / ml · Solution | Articaine, Epinephrine | Canada | Marketed | 2026 |
| ARTICAINE HYDROCHLORIDE AND EPINEPHRINE INJECTION - SP40 mg / ml + 0.01 mg / ml · Solution | Articaine, Epinephrine | Canada | Marketed | 2026 |
| CARBOCAINE 3%30 mg / ml · Solution | Mepivacaine | Canada | Marketed | 2019 |
| DYCLOPRO0.5% | 1% · Solution | Dyclonine | United States | Marketed | 2018 |
| ISOCAINE HYDROCHLORIDE3% · Injectable | Mepivacaine | United States | Not marketed | 1972 |
| ISOCAINE HYDROCHLORIDE W/ LEVONORDEFRIN0.05mg/ml; 2% · Injectable | Levonordefrin, Mepivacaine | United States | Not marketed | 1976 |
| LIDOCAINE 2% AND EPINEPHRINE 1:100,0000.01 mg / ml + 20 mg / ml · Solution | Epinephrine, Lidocaine | Canada | Marketed | 2019 |
| LIDOCAINE 2% AND EPINEPHRINE 1:50,0000.02 mg / ml + 20 mg / ml · Solution | Epinephrine, Lidocaine | Canada | Marketed | 2019 |
| Lignospan 2% Special, injectievloeistofOplossing voor injectie | Epinephrine, Lidocaine | Netherlands | Authorised | 1991 |
| LIGNOSPAN FORTE36 mcg / 1.8 ml + 36 mg / 1.8 ml · Solution | Epinephrine, Lidocaine | Canada | Marketed | 1976 |
| LIGNOSPAN STANDARD18 mcg / 1.8 ml + 36 mg / 1.8 ml · Solution | Epinephrine, Lidocaine | Canada | Marketed | 1976 |
| MARCAINE5 mg / ml + 0.0091 mg / ml · Solution | Bupivacaine, Epinephrine | Canada | Marketed | 2019 |
| OCTOCAINE0.01mg/ml; 2% | 0.02mg/ml; 2% · Injectable | Epinephrine, Lidocaine | United States | Not marketed | 1980 |
| ORAVERSE0.4mg/1.7ml · Injectable | Phentolamine | United States | Marketed | 2008 |
| ORAVERSE0.4 mg / 1.7 ml · Solution | Phentolamine | Canada | Marketed | 2014 |
| PRILOCAINE HYDROCHLORIDE4% · Injectable | Prilocaine | United States | Marketed | 2010 |
| PRILOCAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE0.005mg/ml; 4% · Injectable | Epinephrine, Prilocaine | United States | Marketed | 2011 |
| SCANDONESTSoluzione iniettabile in cartuccia | Epinephrine | Italy | Authorised | |
| SCANDONEST 2% SPECIAL INJ0.01 mg / ml + 20 mg / ml · Liquid | Epinephrine, Mepivacaine | Canada | Not marketed | 1980 |
| SCANDONEST 3% PLAIN INJ30 mg / ml · Solution | Mepivacaine | Canada | Marketed | 1980 |
| Scandonest 3% zonder vasoconstrictor, oplossing voor injectieOplossing voor injectie | Mepivacaine | Netherlands | Authorised | 1990 |
| Scandonest 30 mg/ml otopina za injekcijuotopina za injekciju | Mepivacaine | Croatia | Marketed | 2025 |
| SCANDONEST 30 mg/ml SOLUCION INYECTABLE3000 mg · Solución inyectable | Mepivacaine | Spain | Marketed | 2007 |
| SEPTANESTSoluzione iniettabile | Epinephrine | Italy | Authorised | |
| Septanest 40 mg/ml + 0,005 mg/ml otopina za injekcijuotopina za injekciju | Articaine, Epinephrine | Croatia | Marketed | 2021 |
Where it holds or makes medicines, with how many are current.
| Country | Medicines | Current | Past | Companies |
|---|---|---|---|---|
| Canada | 29 | 17 | 12 | CompaniesAll medicines |
| United States | 8 | 8 | 0 | CompaniesAll medicines |
| Netherlands | 6 | 6 | 0 | CompaniesAll medicines |
| Spain | 5 | 3 | 2 | CompaniesAll medicines |
| Croatia | 3 | 3 | 0 | CompaniesAll medicines |
| Italy | 2 | 2 | 0 | CompaniesAll medicines |
Also in the registers of Brazil, France, Serbia, Singapore, United Kingdom
The ATC groups most of its medicines belong to, largest first.
The active substances in most of its medicines.
How the registers spell it, normalised: legal forms, accents and capitals removed.
Compiled by Prognia from the public medicine and company registers below. Logos are not used.
Companies are grouped by Prognia from the names regulators publish; not an official corporate structure.
Fuente de la información: AEMPS (CIMA).
Licence: AEMPS open data reuse with attribution
Source: U.S. FDA, Drugs@FDA / openFDA. FDA does not endorse this site.
Licence: Public domain (U.S. Government work)
Source: BDPM (ANSM, HAS, UNCAM).
Licence: Licence Ouverte v1.0
Anvisa, official medicine/API manufacturer factual export, HTTP source version Fri, 09 Oct 2026 08:21:54 GMT, acquired 2026-10-09; exact unmodified native identifiers and fields preserved.
Licence: Brazil federal factual open-data reuse; Decreto 8777/2016 consolidated article 4 and third-party exceptions
Health Canada, Drug Product Database, company API, entire response observed 2026-10-10T15:12:05.508784+00:00; native facts projected by Prognia.
Licence: Open Government Licence Canada
Health Canada, Drug Product Database, drugproduct API, entire response observed 2026-10-10T15:12:07.336870+00:00; native facts projected by Prognia.
Licence: Open Government Licence Canada
Fuente de la información: Agencia Española de Medicamentos y Productos Sanitarios www.aemps.gob.es; CIMA presentaciones, acquired 11 October 2026 UTC; each source response/update date retained.
Licence: AEMPS explicit public open-data reuse for citizens and companies; source attribution and update date required
Fuente de la información: Agencia Española de Medicamentos y Productos Sanitarios www.aemps.gob.es; CIMA medicamentos, acquired 11 October 2026 UTC; each source response/update date retained.
Licence: AEMPS explicit public open-data reuse for citizens and companies; source attribution and update date required
BDPM / ANSM, HAS and UNCAM; original URLs and each update date retained
Licence: BDPM exact Licence Ouverte v1.0 (October 2011)
Medicines and Healthcare products Regulatory Agency (MHRA), GOV.UK; Category 2 list; publication updated 25 August 2026; acquired 2026-10-15T08:18:48.423930+00:00; original workbook cells and factual authorization/holder projections adapted under Open Government Licence v3.0.
Licence: Open Government Licence v3.0; exact Crown copyright 2026 publication grant
HALMED, Baza lijekova, source export 08.10.2026., acquired 2026-10-08; factual structured adaptation; Otvorena dozvola RH, NN 67/2017.
Licence: Otvorena dozvola RH
Agenzia Italiana del Farmaco (AIFA); https://drive.aifa.gov.it/farmaci/confezioni_fornitura.csv; HTTP Last-Modified Mon, 12 Oct 2026 23:02:44 GMT; acquired 2026-10-13T17:21:16.224007+00:00; native fields retained, source identifier and role projections are adaptations.
Licence: CC BY 4.0; AIFA published open-data catalog
College ter Beoordeling van Geneesmiddelen, Geneesmiddeleninformatiebank metadata, source update 07-10-2026; downloaded 08-10-2026; factual adaptation.
Licence: Conditional noncreative administrative factual metadata; no dataset-wide CC0 claim
ALIMS, Registar humanih lekova, source 08.10.2026 02:00, downloaded 2026-10-08, https://data.gov.rs/sr/datasets/lekovi-za-upotrebu-u-khumanoj-meditsini/; structured factual adaptation; Serbian Open Data Licence.
Licence: Serbian Open Data Licence (sodl)
Contains information from HSA Listing of Registered Therapeutic Products accessed on 8 October 2026 from data.gov.sg, under Singapore Open Data Licence 1.0: https://data.gov.sg/open-data-licence
Licence: Singapore Open Data Licence
Report an error or request removalCorrections from the company itself are welcome.
Well-known pharmaceutical groups, each with all its companies.